Biogen Inc (BIIB)

282.92
NASDAQ : Health Care
Prev Close 281.44
Day Low/High 280.02 / 283.00
52 Wk Low/High 244.28 / 307.76
Avg Volume 1.56M
Exchange NASDAQ
Shares Outstanding 212.12M
Market Cap 59.70B
EPS 17.00
P/E Ratio 17.63
Div & Yield N.A. (N.A)

Latest News

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen (NASDAQ: BIIB) will present data from its Alzheimer's disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Biogen Appoints Amy Chevalier Efantis Vice President Of Government Affairs

Biogen Appoints Amy Chevalier Efantis Vice President Of Government Affairs

Biogen (NASDAQ: BIIB) announced today the appointment of Amy Chevalier Efantis as Vice President of Government Affairs, effective July 17.

New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA® (nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA® (nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

Biogen (NASDAQ: BIIB) will present robust efficacy and safety data from Phase 2 and 3 SPINRAZA ® (nusinersen) studies at the Cure SMA 2017 Annual SMA Conference in Orlando, Fl, June 29 - July 2, 2017.

Biogen Appoints Catherine Steele Senior Vice President Of Corporate Affairs

Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.

Biogen's IMRALDI®, An Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion By Committee For Medicinal Products For Human Use

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for IMRALDI ® (also known as SB5), an adalimumab biosimilar candidate referencing...

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

The S&P 500 and Dow slip on a crude oil slump.

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Stocks are mixed as energy lags, health care leads.

Biogen Ready for a Big Bounce

Biogen Ready for a Big Bounce

The chart shows this stock has bottomed.

Chart of the Week: Biogen

The chart shows this stock has bottomed.

Biogen To Report Second Quarter 2017 Financial Results And Strategic Update On July 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.

Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17.

Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress

Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress

Positive clinical trial results and newly priced-in competition breed some optimism for UBS Analyst Carter Gould.

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects

Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.

Biogen CFO Bolts to Alexion

Biogen CFO Bolts to Alexion

Chief accounting officer Greg Covino will serve as Biogen's interim principal financial officer while the firm searches for a new finance chief.

Biogen Announces Management Change

Biogen (NASDAQ: BIIB) announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to join another biopharmaceutical company.

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

SPINRAZA® (Nusinersen) Approved In The European Union As First Treatment For Spinal Muscular Atrophy

The European Commission (EC) has granted a marketing authorization for SPINRAZA ® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), Biogen (NASDAQ:BIIB) announced today.

Biogen Announces Webcast Of Virtual Annual Meeting Of Stockholders

Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2017 Annual Meeting of Stockholders will be held on Wednesday, June 7, 2017 at 9:00 a.

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment

Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment

The trial enrolled 1,313 RMS patients in 21 countries for two years of study.